CHICAGO —There is minimal toxicity associated with the use of thalidomide in malignant pleural mesothelioma (MPM); however, there is also no evidence of benefit in progression free survival (PFS) or overall survival (OS), according to researchers at the …

View full post on mesothelioma – Bing News